Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Chimerix Inc (NQ: CMRX )

8.330 USD +0.060 (+0.73%)
Streaming Delayed Price Updated: 10:09 AM EDT, Jun 18, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 148,520
Open 8.200
Bid (Size) 8.320 (29)
Ask (Size) 8.340 (2)
Prev. Close 8.270
Today's Range 8.090 - 8.380
52wk Range 2.220 - 11.57
Shares Outstanding 86,211,412
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – 
From GlobeNewswire News Releases
Chimerix to Present at Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases

Performance

YTD
+75.00%
+75.00%
1 Month
+3.35%
+3.35%
3 Month
-12.87%
-12.87%
6 Month
+53.69%
+53.69%
1 Year
+170.45%
+170.45%

More News

Read More
Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting
From GlobeNewswire News Releases
Chimerix to Present at Cowen and Company 2nd Annual Virtual Oncology Innovation Summit
From GlobeNewswire News Releases
Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update
From GlobeNewswire News Releases
Chimerix to Report First Quarter 2021 Financial Results and Provide an Operational Update on May 6, 2021
From GlobeNewswire News Releases
Chimerix Appoints Vicki Vakiener to Board of Directors
From GlobeNewswire News Releases
Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
From GlobeNewswire News Releases
Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
From GlobeNewswire News Releases
Chimerix, Exclusive Worldwide Licensee of Cantex's Investigational Product, DSTAT, Has Announced Promising Topline Results from the First Cohort of a Randomized COVID-19 Clinical Trial
From PR Newswire
Analysts Expect DWAS To Hit $88
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.